A Role of Circulating biomarkers and Maternal-Infant Outcomes after Anticoagulant Therapy In Pregnant Women with Mechanical Heart Valve Replacement
serum TAT, sP-Selectin, NGAL, and PlGF
Abstract
Aim: To investigate the effect of standardized anticoagulation on parturients and fetuses during pregnancy after mechanical heart valve replacement (MHVR) and to evaluate novel serum biomarkers reflecting coagulation activation, endothelial function, placental perfusion, and renal injury.
Methods: 100 parturients during pregnancy after MHVR who received treatment in Hebei Xingtai People's Hospital from January 2019 to December 2024 were recruited and divided into low-molecular-weight heparin (LMWH) group (n=50) and regional citrate anticoagulation (RCA) group (n=50). Coagulation parameters (PT, APTT, TT, FIB, PLT), novel biomarkers (thrombin-antithrombin complex [TAT], soluble P-selectin [sP-selectin], D-dimer), renal biomarkers (urea nitrogen, serum creatinine, neutrophil gelatinase-associated lipocalin [NGAL], asymmetric dimethylarginine [ADMA]), placental and inflammatory markers (placental growth factor [PlGF], interleukin-6 [IL-6]) were compared between groups. Maternal complications and abnormal fetal development were observed.
Results: PT and APTT of parturients in RCA group markedly surpassed those in LMWH group, TT was notably inferior to that in LMWH group; FIB decreased more and PLT increased more in RCA group; TAT, sP-selectin, and D-dimer levels were significantly lower in RCA group (P<0.05). After anticoagulant therapy, urea nitrogen and serum creatinine of parturients in RCA group decreased more than those in LMWH group; NGAL and ADMA levels demonstrated greater reduction in RCA group (P<0.05). PlGF levels were significantly higher and IL-6 levels were significantly lower in RCA group (P<0.05). The incidence of various complications in parturients with MHVR in RCA group was obviously inferior to that in parturients with LMWH group (22% vs. 48%, P<0.05), and the incidence of gastrointestinal bleeding was the highest in parturients after MHVR. The probability of fetal dysplasia in LMWH group drastically surpassed that in RCA group (18% vs. 8%, P<0.05).
Conclusion: RCA has better effect for parturients and fetuses after MHVR, can apparently improve coagulation indicators and renal function, reduce maternal complications and fetal dysplasia. Novel biomarker profiles indicate that RCA reduces thrombin generation, platelet activation, endothelial injury, and systemic inflammation, while enhancing placental angiogenesis. RCA demonstrates high safety and is worthy of wide clinical application.
References
2. Song F, Liu FZ, Liang YF, Tse G, Li X, Liao HT, Chen JY. Clinical, sonographic characteristics and long-term prognosis of valvular heart disease in elderly patients. J Geriatr Cardiol. 2019;16(1):33-41.
3. Hong ZN, Huang JS, Huang LQ, Cao H, Chen Q. The effect of valve noise on the quality of life of patients after mechanical mitral valve replacement in a Chinese population. J Cardiothorac Surg. 2019;14(1):137.
4. Bellaing AM de, Raisky O, Haydar A, Bonnet D, Bajolle F. Aortic valve replacement by mechanical prosthesis in children: A positive long-term outcome including for patients with an infantile Marfan syndrome. Arch Cardiovasc Dis Suppl. 2019;11(1):137-138.
5. Azari S, Rezapour A, Omidi N, Alipour V, Tajdini M, Sadeghian S, Bragazzi NL. A systematic review of the cost-effectiveness of heart valve replacement with a mechanical versus biological prosthesis in patients with heart valvular disease. Heart Fail Rev. 2020;25(3):495-503.
6. Wang Q, Gao Y, Xi W, Shen H, Wang J, Xiao J, Wang Z. Mechanical valve replacement for congenital heart disease complicated by native pulmonary valve endocarditis: a case report and literature review. Heart Surg Forum. 2018;21(2):E096-E098.
7. Bianchini EP, Fazavana J, Picard V, Borgel D. Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives. Blood. 2011;117(6):2054-60.
8. Stam J, Lensing AW, Vermeulen M, Tijssen JG. Heparin treatment for cerebral venous and sinus thrombosis. Lancet. 1991;338(8775):1154.
9. Lev-Ran O, Kramer A, Gurevitch J, Shapira I, Mohr R. Low-molecular-weight heparin for prosthetic heart valves: treatment failure. Ann Thorac Surg. 2000;69(1):264-6.
10. Miller GA, Sutton GC, Kerr IH, Gibson RV, Honey M. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Med J. 1971;2(5763):681-4.
11. Sun Y, Chen C, Zhang X, Wang S, Zhu R, Zhou A, Chen S, Feng J. Heparin improves alveolarization and vascular development in hyperoxia-induced bronchopulmonary dysplasia by inhibiting neutrophil extracellular traps. Biochem Biophys Res Commun. 2020;522(1):33-39.
12. Yang Y, Li M, Fu S. Use of highly-stable and covalently bonded polymer colorant on binder-free pigment printing of citric acid treated cotton fabric. Cellulose. 2021;28(3):1843-1856.
13. Jamadar N, Nagoba B, Davane M, Ahmed A, Tangsal A. Citric acid treatment of oral ulcers refractory to conventional treatment: a case study. J Wound Care. 2019;28(7):461-463.
14. Huang J, Zhou Z, Ali M, Gu X, Danish M, Sui Q, Lyu S. Degradation of trichloroethene by citric acid chelated Fe(II) catalyzing sodium percarbonate in the environment of sodium dodecyl sulfate aqueous solution. Chemosphere. 2021;281:130798.
15. Kwon HW, Kim WH, Lee JR, Kwak JG, Cho S, Bae EJ, Kim GB. Outcomes of supra-annular mechanical atrioventricular valve replacement with polytetrafluoroethylene graft in infants and children. Pediatr Cardiol. 2020;41(3):607-614.
16. Torres JA, Arevalo A, Sastre JA, González-Porras JR, Salvador R, González-Santos J, Lozano FS. Spontaneous rupture of a mechanical valve in a mitral position (On-X) with migration-embolization to aortic bifurcation from the perspective of the vascular surgeon. J Cardiovasc Surg (Torino). 2020;61(2):256-263.
17. Amorós Rivera C, López Rodríguez FJ, Arnáiz García ME, Arévalo Abascal RA, Barral Varela AM, López Tatis MM, Sastre JA, Lozano Sánchez F, Torres Hernández JÁ, González Santos JM. Survival after mitral valve replacement for leaflet escape in a contemporary on-X mechanical valve. Ann Thorac Surg. 2019;108(5):e307-e309.
18. Berth-Jones J, Hutchinson PE, Wicks AC, Mitchell VE. Chronic urticaria with angio-oedema controlled by warfarin. BMJ. 1988;297(6660):1382-3.
19. Alnaqeeb M, Mansor KA, Mallah EM, Ghanim BY, Idkaidek N, Qinna NA. Critical pharmacokinetic and pharmacodynamic drug-herb interactions in rats between warfarin and pomegranate peel or guava leaves extracts. BMC Complement Altern Med. 2019;19(1):29.
20. Schved JF, Gris JC, Eledjam JJ. Circadian changes in anticoagulant effect of heparin infused at a constant rate. Br Med J (Clin Res Ed). 1985;290(6477):1286.
21. Schreurs HH, Wijers MJ, Gu YJ, van Oeveren W, van Domburg RT, de Boer JH, Bogers AJ. Heparin-coated bypass circuits: effects on inflammatory response in pediatric cardiac operations. Ann Thorac Surg. 1998;66(1):166-71.
22. Moncrieff MW, Glasgow EF. Haemolytic-uraemic syndrome treated with heparin. Br Med J. 1970;3(5716):188-91.
23. Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med. 2009;37(2):545-52.
24. Deguchi K, Noguchi M, Yuwasaki E, Deguchi A, Wada H, Murashima S, Nishikawa M, Shirakawa S. Dynamic fluctuations in blood of thrombin/antithrombin III complex (TAT). Am J Hematol. 1991;38(2):86-9.
25. Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J. 2003;24(24):2166-79.
26. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood. 2009;113(13):2878-87.
27. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365(9466):1231-8.
28. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339(8793):572-5.
29. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672-83.
30. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101(15):1767-72.
Copyright (c) 2026 Shaohui Li Shaohui Li
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.